LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have beenaccepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the […]
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces its unaudited half-year report for the six months ended 30 June 2024. Strong progress with our LungLB® product Continued operational delivery : Financial Highlights: Commenting Paul Pagano, Chief Executive […]
LungLife AI licensure/accreditation information posted here.